Eurosurv. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons

[tetano]

Open Access Like 0

Download



[h=2]Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons

[/h]

• Larisa V Gubareva[SUP]1[/SUP], Vasiliy P Mishin[SUP]1[/SUP], Mira C Patel[SUP]1,2[/SUP], Anton Chesnokov[SUP]1[/SUP], Ha T Nguyen[SUP]1,2[/SUP], Juan De La Cruz[SUP]1,2[/SUP], Sarah Spencer[SUP]1[/SUP], Angela P Campbell[SUP]1[/SUP], Mallory Sinner[SUP]3[/SUP], Heather Reid[SUP]3[/SUP], Rebecca Garten[SUP]1[/SUP], Jackie M Katz[SUP]1[/SUP], Alicia M Fry[SUP]1[/SUP], John Barnes[SUP]1[/SUP], David E Wentworth[SUP]1[/SUP]

The anti-influenza therapeutic baloxavir targets cap-dependent endonuclease activity of polymerase acidic (PA) protein. We monitored baloxavir susceptibility in the United States with next generation sequencing analysis supplemented by phenotypic one-cycle infection assay. Analysis of PA sequences of 6,891 influenza A and B viruses collected during 2016/17 and 2017/18 seasons showed amino acid substitutions: I38L (two A(H1N1)pdm09 viruses), E23G (two A(H1N1)pdm09 viruses) and I38M (one A(H3N2) virus); conferring 4?10-fold reduced susceptibility to baloxavir.

full article

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2019.24.3.1800666#abstract_content